Related Experiment Video
Updated: Jan 20, 2026
Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma
Published on: November 4, 2010
[Use of antibiotics for asthma and COPD exacerbation]
1Erasmus MC, afd. Longziekten, Rotterdam.
Abstract:
Most patients with asthma do not receive antibiotics when they experience an exacerbation. In contrast, most patients with COPD exacerbations do indeed receive antibiotics. However, studies have shown that while some subgroups of patients with asthma or COPD may benefit from antibiotics, others do not. In this era of antibiotic stewardship, it is of crucial importance to use objective criteria when deciding whether or not to give antibiotics. Biomarkers, such as procalcitonin, could be helpful when making this decision. There is a clear need for well-designed and high-quality studies with enough power to evaluate the usage of these kinds of biomarkers.
Insights
Antibiotic use for asthma and COPD exacerbations varies, with biomarkers like procalcitonin potentially guiding better treatment decisions. More research is needed to confirm their effectiveness in guiding antibiotic stewardship.
Area of Science:
- Pulmonology
- Infectious Diseases
- Clinical Pharmacology
Background:
- Antibiotic prescription patterns differ significantly between asthma and COPD exacerbations.
- Evidence suggests that only specific patient subgroups benefit from antibiotics during exacerbations.
- Current antibiotic use may not align with antimicrobial stewardship principles.
Purpose of the Study:
- To highlight the need for objective criteria in guiding antibiotic decisions for respiratory exacerbations.
- To explore the potential role of biomarkers, such as procalcitonin, in optimizing antibiotic therapy.
- To emphasize the necessity of robust clinical trials for evaluating biomarker-guided antibiotic use.
Main Methods:
- This study is a review and analysis of current clinical practices and research findings.
- It examines existing literature on antibiotic use in asthma and COPD exacerbations.
- It discusses the potential application of biomarkers like procalcitonin in clinical decision-making.
Main Results:
- Most asthma exacerbations are not treated with antibiotics, unlike COPD exacerbations.
- The efficacy of antibiotics is subgroup-dependent in both asthma and COPD.
- Procalcitonin is identified as a promising biomarker for guiding antibiotic therapy.
Conclusions:
- Objective criteria and biomarkers are essential for judicious antibiotic use in respiratory exacerbations.
- Further high-quality, powered studies are required to validate the role of biomarkers in antibiotic stewardship.
- Personalized treatment approaches based on biomarkers can improve outcomes and reduce unnecessary antibiotic exposure.
Related Concept Videos
00:57Antibiotic Selection
01:29Asthma-I: Introduction
01:20COPD: Pathogenesis and Clinical Features
The primary cause for the onset of COPD is cigarette smoking and exposure to air pollution. These hazardous factors initiate a chain reaction within the lungs, resulting in chronic inflammation, damage to the airways, and a...
01:26COPD: Management Using Bronchodilators and Corticosteroids
01:26Asthma-II: Pathophysiology and Classification
Additionally, environmental and genetic factors play crucial roles in determining an individual's susceptibility to asthma and the severity of their condition.
Critical processes in asthma pathophysiology include:
01:20Asthma: Pathogenesis and Management
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.